Financial Performance - The company's operating revenue for Q1 2021 was ¥141,827,415.71, representing a 284.06% increase compared to ¥36,928,882.41 in the same period last year[7] - Net profit attributable to shareholders was ¥15,277,393.73, a significant increase of 793.48% from a loss of ¥2,203,004.31 in the previous year[7] - Basic earnings per share rose to ¥0.18, up 700.00% from a loss of ¥0.03 per share in the previous year[7] - The company achieved operating revenue of CNY 141.83 million in Q1 2021, a year-on-year increase of 284.06% due to recovery from the pandemic's impact in the previous year[15] - The net profit attributable to shareholders reached CNY 15.28 million, compared to a loss of CNY 2.20 million in the same period last year, driven by normalized sales and procurement logistics[17] - The company reported a total profit of CNY 18,107,233.71, compared to a total loss of CNY 2,203,004.31 in the previous year[39] - The company reported an operating profit of CNY 17,650,222.77, compared to an operating loss of CNY 2,179,409.47 in the previous year[39] Cash Flow - The net cash flow from operating activities improved to ¥13,908,393.23, compared to a negative cash flow of ¥17,820,932.10 in the same period last year, marking a 178.05% increase[7] - The cash inflow from operating activities amounted to CNY 127,979,909.60, significantly up from CNY 14,271,658.82 in the previous period[46] - The net cash flow from operating activities was CNY 13,908,393.23, recovering from a negative CNY -17,820,932.10 in the prior year[47] - Cash inflow from financing activities was CNY 59,267,222.22, an increase from CNY 50,000,000.00 in the previous period[48] - The net cash flow from financing activities was CNY 834,313.35, down from CNY 13,377,459.58 in the prior year[48] - The company experienced a net decrease in cash and cash equivalents of CNY 12,475,078.01, contrasting with a decrease of CNY -7,980,886.65 in the previous year[48] Assets and Liabilities - Total assets at the end of the reporting period were ¥826,762,043.44, reflecting a 2.78% increase from ¥804,426,535.29 at the end of the previous year[7] - The company's current assets totaled CNY 604,826,734.34, up from CNY 579,642,443.60 at the end of 2020, indicating an increase of about 4.27%[29] - Total liabilities rose to CNY 272,052,008.25 from CNY 264,579,247.03, indicating an increase of approximately 2.8%[31] - The company's equity attributable to shareholders increased to CNY 549,334,993.07 from CNY 534,540,315.19, reflecting a growth of about 2.76%[32] Research and Development - Research and development expenses increased by 196.22% to CNY 6.58 million, reflecting a return to normal R&D activities after pandemic-related restrictions[15] - Research and development expenses increased to CNY 6,580,076.26 from CNY 2,221,362.76, reflecting the company's commitment to innovation[38] Shareholder Information - The top shareholder, Xi Zubin, holds 42.38% of the shares, totaling 36,567,000 shares[11] - The company reported no changes in the number of shares due to new issuance or other reasons affecting equity[7] Government Support - The company received government subsidies amounting to ¥915,351.97 during the reporting period[8] Operational Developments - The company signed a significant order with its top five suppliers, with procurement amount increasing by 386.84% year-on-year, indicating a recovery in supply chain operations[17] - The company initiated a top-level design for its ERP system to enhance operational efficiency and standardization in response to its expanding scale[20] - The company plans to expand its product and technology offerings in the steroid drug sector, including a joint venture to produce 300 tons of acetate and 200 tons of 17α-hydroxyprogesterone annually[20] Tax and Fees - The company reported a 379.80% increase in business tax and additional fees, attributed to the recovery of revenue following the pandemic[15] Other Financial Information - Total operating costs amounted to CNY 123,053,088.90, compared to CNY 39,411,549.29 in the previous year, indicating a rise in costs associated with increased revenue[38] - Other income for the quarter was CNY 439,839.26, an increase from CNY 303,257.41 in the same period last year[38] - The total comprehensive income for the first quarter was CNY 263,665.07, a decrease from CNY -651,666.73 in the previous period[44] - Basic and diluted earnings per share were both CNY 0.0031, compared to CNY -0.0076 in the same period last year[44] Audit Information - The company has not undergone an audit for the first quarter report[53]
共同药业(300966) - 2021 Q1 - 季度财报